title: Effects of XW630 on bone formation in ovariectomized rats and in human osteoblast-like cells.
abstract: OBJECTIVE
  To study the effects of XW630 on bone formation in overiectomized (OVX) rats and in human osteoblast-like cell line TE85.
  
  
  METHODS
  Bone histomorphometric analysis was performed with undecalcified bone sections and tetracycline intraperitoneally labeling.
  
  
  RESULTS
  Compared with that of OVX rats, the static data of trabecular bone volume (TBV)/total tissue volume (TTV), TBV/sponge bone volume (SBV) and mean trabecular plate density (MTPD) were enhanced while mean trabecular plate spacing (MTPS) decreased after treated with XW630 for 13w. The dynamic data of single-labeled surface [Sfract(s)], double-labeled surface [Sfract(d)], Sfract(d+1/2s), trabecular osteoid surface (TOS) and bone formation rate in tissue level (Svf) were increased and osteoid maturation period (OMP) shortened in XW630 group. In osteoblast-like cells, both 3H-thymidine incorporation and cell count increased after treated with XW630 for 48. Treated with XW630 for 12 approximately 18h, inducible nitric oxide synthase (iNOS) activity and cGMP content increased in time-dependent manners.
  
  
  CONCLUSIONS
  XW630 enhanced bone activation frequency and increased trabecular connectivity, stability, and strength. The cellular mechanism related to effects of XW630 on bone formation in ovariectomized rats.
authors.affiliation: Department of Pharmacology, Institute of Basic Medical Sciences, CAMS & PUMC, Beijing 100005.
authors.forename: L
authors.initials: L
authors.lastname: Sun
authors.forename: M
authors.initials: M
authors.lastname: Qiu
authors.forename: L
authors.initials: L
authors.lastname: Weng
authors.forename: H
authors.initials: H
authors.lastname: Zheng
authors.forename: J
authors.initials: J
authors.lastname: Liu
mesh_terms: D000818:Animals; D001859:Bone Neoplasms / Q000473:pathology; D002455:Cell Division / Q000187:drug effects; D006152:Cyclic GMP / Q000378:metabolism; D004970:Estrone / Q000494:pharmacology; D005260:Female; D005269:Femur / Q000187:drug effects; D006801:Humans; D019001:Nitric Oxide Synthase / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II; D010006:Osteoblasts / Q000166:cytology* / Q000378:metabolism; D010012:Osteogenesis / Q000187:drug effects*; D012516:Osteosarcoma / Q000473:pathology; D010052:Ovariectomy; D010879:Piperazines / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D013752:Tetracycline / Q000494:pharmacology*; D013754:Tetracyclines; D014407:Tumor Cells, Cultured
chemical_list: C428143:2-(3-estrone-N-ethyl-piperazine-methyl)tetracycline; D010879:Piperazines; D013754:Tetracyclines; D004970:Estrone; C496319:NOS2 protein, human; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; C496318:Nos2 protein, rat; D013752:Tetracycline; D006152:Cyclic GMP